Type 2 diabetes medicines and continuing your treatment
Type 2 diabetes is treated in steps, and the tablets used belong to groups that lower blood sugar in different ways. Metformin is usually the first, and an SGLT2 inhibitor such as empagliflozin, a DPP-4 inhibitor such as sitagliptin or a sulfonylurea such as gliclazide can be added when blood sugar stays above target. This page explains what each group does, which results the doctor reviews and when an examination is needed instead.
How type 2 diabetes is treated
Treatment rests on two things at once: eating, activity and weight on one side, medicines on the other. The summaries of product characteristics of these medicines describe them as an addition to diet and exercise when these alone do not control blood sugar well enough, not as a replacement. The symptoms that usually lead to the diagnosis are described in our guide to the symptoms of type 2 diabetes.
Medicines are normally introduced in steps. One is started, the effect is measured with glycated haemoglobin (HbA1c), and a medicine from a different group is added when blood sugar stays above the target agreed with your doctor. Fixed combinations in a single tablet, such as sitagliptin with metformin or empagliflozin with metformin, exist for that reason; a combination is one prescription but still two medicines, and the cautions for both apply.
In the Medicines Authority register, all authorised products of the tablets described on this page are prescription-only medicines (POM), and the centrally authorised EU products are subject to medical prescription.
Metformin: usually the first medicine
Metformin reduces the amount of glucose the liver produces and helps the body use glucose, in part by increasing the action of its own insulin. Because it does not stimulate insulin release, it does not cause low blood sugar on its own, and in clinical studies body weight stayed stable or fell slightly. There is more in our page on metformin.
The digestive system accounts for the commonest side effects, particularly at the start: nausea, vomiting, diarrhoea, abdominal pain and loss of appetite, which settle in most people. Taking it during or after meals in two or three doses and building the dose up slowly helps, and prolonged-release tablets are also authorised. A change in taste and a fall in vitamin B12 are also common.
Kidney function decides the dose. It is measured before treatment and at least once a year, and metformin is not used when it falls below an eGFR of 30 ml/min. Metformin is paused if you become dehydrated through severe diarrhoea, vomiting, fever or drinking too little, and around scans with iodinated contrast and surgery under general, spinal or epidural anaesthesia, restarting no earlier than 48 hours afterwards once kidney function has been checked.
Lactic acidosis is very rare but serious. Difficult breathing, abdominal pain, muscle cramps, marked weakness and feeling cold mean you should stop metformin and get medical help immediately.
SGLT2 inhibitors: empagliflozin and dapagliflozin
SGLT2 inhibitors make the kidneys pass more glucose out in the urine. Empagliflozin and dapagliflozin belong to this group; in the clinical studies described in the empagliflozin product information, body weight and blood pressure also fell a little. Both are authorised for type 2 diabetes, and also for symptomatic chronic heart failure and chronic kidney disease, so the same tablet may have been prescribed for a reason other than blood sugar. The reason for starting it belongs in your answers. Our page on empagliflozin has more detail.
Because sugar passes in the urine, genital fungal infections are common and urinary infections occur; complicated urinary infections, including kidney infection, have been reported. Pain, tenderness, redness or swelling of the genital or perineal area together with fever or feeling unwell needs urgent medical attention, because a rare but serious infection of the tissues there has been reported with this group.
Ketoacidosis can develop even when blood sugar is only moderately raised. Nausea, vomiting, loss of appetite, abdominal pain, excessive thirst, difficult breathing, confusion or unusual tiredness need to be assessed by a doctor without waiting, whatever your blood sugar reading. Treatment is interrupted for major surgery or a serious acute illness in hospital, and a drop in blood pressure or dehydration is more likely if you are 75 or over or take a diuretic.
DPP-4 inhibitors: sitagliptin and linagliptin
DPP-4 inhibitors block the enzyme that breaks down the incretin hormones released by the gut after a meal, so more of them stay active; this increases insulin release and lowers the release of glucagon. Sitagliptin and linagliptin belong to this group. In the sitagliptin studies body weight did not increase, and on its own or with metformin low blood sugar was about as frequent as with placebo. With insulin or a sulfonylurea it was more frequent, so a lower dose of those may be considered. Our page on sitagliptin has more detail.
Headache is a common side effect, and infections of the upper airways and joint pain have been reported; severe or persistent joint pain is a reason to have the medicine reviewed rather than to put up with it. Acute pancreatitis has been linked to this group: persistent, severe abdominal pain is the characteristic symptom and needs urgent medical attention, and the medicine is stopped if pancreatitis is suspected. Serious allergic reactions, including swelling of the face and throat and severe skin reactions, have occurred, within the first three months of treatment in the reported cases, and blisters on the skin can be a sign of bullous pemphigoid.
Kidney function affects the choice within the group: sitagliptin is given at a lower dose when the eGFR is below 45 ml/min, while linagliptin needs no dose adjustment for kidney impairment.
Gliclazide, a sulfonylurea
Gliclazide lowers blood sugar by stimulating the pancreas to release insulin. The Medicines Authority register lists eight authorised gliclazide products, all POM, including modified-release tablets of 30 mg and 60 mg. The modified-release tablet is taken once a day at breakfast, swallowed without crushing or chewing, and it can be combined with metformin or with insulin.
Low blood sugar (hypoglycaemia) is the main risk and can be severe and prolonged. Its summary says gliclazide should be prescribed only if you are likely to eat regularly, including breakfast; late or small meals, low-calorie diets, strenuous exercise, alcohol, kidney or liver problems and some other medicines all raise the risk. Gliclazide is not used in type 1 diabetes, in severe kidney or liver failure, with the antifungal miconazole or while breastfeeding, and it needs caution if you have G6PD deficiency.
Which results the doctor reviews before you continue
To continue a medicine, the doctor needs to know which medicines you take, at which strength and on which schedule, who started them and when, and whether anything was recently changed, added or stopped.
The results that matter most are a recent HbA1c, kidney function and weight, together with blood pressure. The summaries of metformin and empagliflozin ask for kidney function to be measured at least once a year. Readings you take at home help as well, particularly when they show low values or wide swings during the day.
How often HbA1c is measured is a decision for the doctor who treats your diabetes: usually more often after a change of treatment and less often once the result has been stable. What matters for continuing is that the last result is recent enough to describe your present situation.
Episodes of low blood sugar, problems with your feet, changes in vision, swelling of the ankles and shortness of breath all belong in your answers, because each of them can change what should be prescribed.
Starting treatment, and when an examination comes first
A first prescription is possible where recent results and your answers give clear indications; without them the doctor asks for tests, recommends an examination in Malta or declines. For some conditions, and in some individual cases, it is advisable to see a doctor in person; the doctor may recommend this.
Starting insulin or changing its dose needs measured blood sugar values, teaching about low blood sugar and regular contact with a doctor, and none of that can be done from a questionnaire. For insulin, the right route is your doctor or a diabetes clinic in Malta.
Rapidly rising values, repeated low blood sugar, unexplained weight loss, vomiting, drowsiness or the smell of acetone on the breath need urgent care. Chest pain, breathlessness or sudden weakness are emergencies: ring 112 or go to Accident and Emergency.
Pregnancy and planning a pregnancy change the treatment. The gliclazide summary names insulin as the first choice in pregnancy and advises changing to it before you try to conceive; empagliflozin should preferably be avoided in pregnancy and sitagliptin should not be used, while metformin can be considered if clinically needed. Regular checks of your eyes, feet and kidneys stay with your family doctor or diabetes clinic.
How a request is reviewed
The medical questionnaire you fill in covers the medicine, your health and your other medicines, whether the request is for a medicine you already take or, where the doctor finds clear indications, a new one. If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. In that chat the doctor may want recent results or a blood pressure reading from you, and may advise you to consult a doctor in Malta, or decline. There is no video call, no phone call and no live chat. GLP-1 medicines are assessed only through Weight Loss Treatment.
If the doctor issues a prescription, you receive it as a PDF by email. You print it and bring it on paper to a pharmacy in Malta together with photo identification. Your prescription is issued in the standard EU cross-border format set out in Directive 2012/52/EU. A pharmacy in Malta may dispense it; the decision rests with the pharmacist. Take the prescription to a pharmacy within six months of the date on it; a prescription for an antibiotic cannot be dispensed more than ten days after its date of issue.
What does it cost?
A prescription from this review is private. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full.
Look at the button on this page for the review fee. The fee covers the medical consultation, not the issuing of a document. If the doctor declines on medical or legal grounds, we refund the fee. If the doctor asks you for documents, you have at least 7 days to send them in and we send you a reminder; if you ask us, we agree a longer deadline. If the case still cannot be completed, we close the request, let you know and refund the fee in full. Your medicine is a separate cost.
Who reviews your request?
Damian Wojno, a doctor registered with the Polish Medical Chamber, licence no. 3211301, assesses the requests on this page. The doctor is not registered with the Medical Council of Malta. Your family doctor or diabetes clinic keeps its role; this review does not replace it.
Which medicine is used first in type 2 diabetes?
Metformin is usually the first medicine. It reduces the glucose the liver produces, helps the body use its own insulin, does not cause low blood sugar on its own and in studies kept weight stable or lowered it slightly. The product information for empagliflozin and dapagliflozin describes their use on their own when metformin is not tolerated, and the choice belongs to the doctor.
How often is HbA1c checked?
The interval is set by the doctor who treats your diabetes: usually more often after a change of treatment and less often once the result has been stable. To continue a medicine, what matters is that the last result is recent enough to describe your present situation, with its date, rather than a value remembered from a year ago.
Can diabetes medicines be combined?
They often are. Metformin is frequently combined with an SGLT2 inhibitor, a DPP-4 inhibitor or gliclazide, and fixed combinations in a single tablet exist. A combination is one prescription but still two medicines, so the cautions for both apply. Combining with insulin or a sulfonylurea raises the risk of low blood sugar, so doses may need to be lowered.
Which side effects are common with diabetes tablets?
With metformin, digestive effects such as nausea, diarrhoea and abdominal pain, a change in taste and a fall in vitamin B12. With SGLT2 inhibitors, genital fungal infections, urinary infections and thirst. With DPP-4 inhibitors, headache. With gliclazide, low blood sugar. Full lists are in the leaflet in the box and in the summary of product characteristics.
What does the doctor need before you continue a diabetes medicine?
The names, strengths and schedules of the medicines you take, who started them and when, and anything recently changed or stopped. Then a recent HbA1c, kidney function, weight and blood pressure, with dates, plus readings taken at home if you have them. Episodes of low blood sugar, foot problems, changes in vision, ankle swelling and breathlessness belong in your answers too.
Is insulin part of this review?
Starting insulin or adjusting its dose needs measured blood sugar values, teaching about low blood sugar and regular contact with a doctor, and none of that can be done from a questionnaire. For insulin, the right route is your doctor or a diabetes clinic in Malta.
Are diabetes medicines on this prescription covered by POYC?
Our prescription is private and sits outside the POYC scheme, which means the medicine is paid for at the pharmacy in full. It is not an ePrescription and does not appear in myHealth.
Will a pharmacy in Malta dispense a prescription from a doctor elsewhere in the EU?
A prescription from a doctor in another EU country can be dispensed in Malta (Article 81(3) of the Medicines Act, Cap. 458) if the pharmacist can confirm the doctor's licence. The decision rests with the pharmacist, who may refuse. Have the printed prescription and photo identification with you.
- Medicines Authority: Brotmin 500mg film-coated tablets, metformin (MA032/14201)
- Medicines Authority: Diamicron MR Tablets 60, gliclazide (MA066/00603)
- EMA: Jardiance (empagliflozin) product information
- EMA: Forxiga (dapagliflozin) product information
- EMA: Januvia (sitagliptin) product information
- EMA: Trajenta (linagliptin) product information
- Prescription and Dispensing Requirements Rules (S.L. 458.49), rule 4 (legislation.mt)
- Medicines Act (Cap. 458), Article 81 (legislation.mt)